



WHAT IS CLAIMED IS:

1. A c-Kit kinase inhibitor comprising as an active ingredient, a compound represented by the general formula (I), a salt thereof or a hydrate of the foregoing:



(wherein R^1 represents methyl, 2-methoxyethyl or a group represented by the formula (II):



10 (wherein R^{a3} represents methyl, cyclopropylmethyl or cyanomethyl; R^{a1} represents hydrogen, fluorine or hydroxyl; and R^{a2} represents 1-pyrrolydinyl, 1-piperidinyl, 4-morpholinyl, dimethylamino or diethylamino);

15 R^2 represents cyano or $-CONHR^{a4}$ (wherein R^{a4} represents hydrogen, C_{1-6} alkyl, C_{3-8} cycloalkyl, C_{1-6} alkoxy or C_{3-8} cycloalkoxy);

R^3 represents hydrogen, methyl, trifluoromethyl,

chlorine or fluorine; and

R⁴ represents hydrogen, methyl, ethyl, n-propyl, cyclopropyl, 2-thiazolyl or 4-fluorophenyl).

2. The c-Kit kinase inhibitor according to claim
5 1, wherein R¹ represents methyl.

3. The c-Kit kinase inhibitor according to claim
1, wherein R⁴ represents methyl, ethyl or cyclopropyl.

4. The c-Kit kinase inhibitor according to claim
1, wherein R³ represents hydrogen, chlorine or fluorine.

10 5. The c-Kit kinase inhibitor according to claim
1, wherein R² represents -CONHR^{a4} (wherein R^{a4}
represents hydrogen or methoxy).

15 6. The c-Kit kinase inhibitor according to claim
1, wherein the compound represented by the general
formula (I) is a compound selected from the group
consisting of 4-(3-chloro-4-
(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-
quinolinecarboxamide, 4-(3-chloro-4-
(ethylaminocarbonyl)aminophenoxy)-7-methoxy-6-
quinolinecarboxamide, N6-methoxy-4-(3-chloro-4-
(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-
6-quinolinecarboxamide and N6-methoxy-4-(3-chloro-4-
(((ethylamino)carbonyl)amino)phenoxy)-7-methoxy-6-
quinolinecarboxamide.

20 7. An anticancer agent for treating a cancer
expressing excessive c-Kit kinase or a mutant c-Kit

kinase, comprising as an active ingredient, the c-Kit kinase inhibitor according to claim 1.

8. The anticancer agent according to claim 7,
wherein the cancer expressing excessive c-Kit kinase or
5 a mutant c-Kit kinase is acute myelogenous leukemia,
mast cell leukemia, a small cell lung cancer, GIST, a
testicular cancer, an ovarian cancer, a breast cancer,
a brain cancer, neuroblastoma or a colorectal cancer.

9. The anticancer agent according to claim 7,
10 wherein the cancer expressing excessive c-Kit kinase or
a mutant c-Kit kinase is acute myelogenous leukemia, a
small cell lung cancer or GIST.

10. The anticancer agent according to claim 7,
which is applied to a patient for which a cancer
15 expressing excessive c-Kit kinase or a mutant c-Kit
kinase is identified.

11. A therapeutic agent for mastocytosis, allergy
or asthma, comprising as an active ingredient, the c-
Kit kinase inhibitor according to claim 1.

20 12. A therapeutic method for a cancer, comprising
administering to a patient suffering from a cancer
expressing excessive c-Kit kinase or a mutant c-Kit
kinase, a pharmacologically effective dose of the c-Kit
kinase inhibitor according to claim 1.

25 13. The method according to claim 12, wherein the
cancer expressing excessive c-Kit kinase or a mutant c-

Kit kinase is acute myelogenous leukemia, mast cell leukemia, a small cell lung cancer, GIST, a testicular cancer, an ovarian cancer, a breast cancer, a brain cancer, neuroblastoma or a colorectal cancer.

5 14. The method according to claim 12, wherein the cancer expressing excessive c-Kit kinase or a mutant c-Kit kinase is acute myelogenous leukemia, a small cell lung cancer or GIST.

10 15. A therapeutic method for a cancer, comprising the steps of:

extracting cancer cells from a patient suffering from a cancer;

15 confirming that the cancer cells are expressing excessive c-Kit kinase or a mutant c-Kit kinase; and administering to the patient a pharmacologically effective dose of the c-Kit kinase inhibitor according to claim 1.

20 16. A therapeutic method for mastocytosis, allergy or asthma, comprising administering to a patient suffering from the disease, a pharmacologically effective dose of the c-Kit kinase inhibitor according to claim 1.

25 17. A method for inhibiting the c-Kit kinase activity, comprising applying to a cell expressing excessive c-Kit kinase or a mutant c-Kit kinase, a pharmacologically effective dose of the c-Kit kinase

inhibitor according to claim 1.